Pharmaceutical composition for treating fibrosis comprising SGLT-2 inhibitor and angiotensin receptor blocker
A pharmaceutical composition combining SGLT-2 inhibitors and angiotensin receptor blockers effectively treats fibrosis by reducing renal fibrosis markers, demonstrating synergistic renal protection in a mouse model.
WO2026141971A1PCT designated stage Publication Date: 2026-07-02AUTOTELIC BIO INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- AUTOTELIC BIO INC
- Filing Date
- 2025-11-17
- Publication Date
- 2026-07-02
Smart Images
Figure KR2025018927_02072026_PF_FP_ABST
Abstract
The present invention relates to a pharmaceutical composition for treating fibrosis comprising an SGLT-2 inhibitor and an angiotensin receptor blocker. Specifically, after inducing renal fibrosis in C57BL / 6 mice by administering folic acid, dapagliflozin and olmesartan medoxomil as test substances were administered alone or in combination for 4 weeks. As a result of albumin to creatinine ratio (ACR) in dapagliflozin alone and dapagliflozin + olmesartan co-administered groups, it is determined from histological analysis results of renal tissue that the dapagliflozin + olmesartan co-administered groups exhibit superior renal fibrosis-ameliorating and renoprotective effects compared with each of the single-administration groups of dapagliflozin or olmesartan medoxomil.
Need to check novelty before this filing date? Find Prior Art